Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06265870

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia

Led by Prince of Songkla University · Updated on 2024-09-24

700

Participants Needed

1

Research Sites

87 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.

CONDITIONS

Official Title

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Absolute eosinophil count greater than 500 cells/microliter with white blood cell count less than 10,000 cells/microliter
  • Consent to participate in the research
Not Eligible

You will not qualify if you...

  • Need for urgent care due to significant unintended weight loss over 10% in 6 months, fever of 37.8°C or higher, lymphadenopathy, hepatosplenomegaly, or presence of blast cells in blood
  • Received anthelminthic drugs within the past 6 months
  • Active cancer, HIV, hepatitis B, hepatitis C, collagen vascular disease, or active tuberculosis
  • Allergy to albendazole, ivermectin, or metronidazole
  • Pregnancy or lactation
  • Serum transaminase levels more than twice the upper normal limit
  • Taking medications that may induce eosinophilia in the past 3 months, including herbal supplements, NSAIDs, salicylic acid, carbamazepine, colchicine, nitrofurantoin, dapsone, or minocycline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Prince of Songkla University - Hat Yai Campus: Prince of Songkla University

Hat Yai, Changwat Songkhla, Thailand, 90110

Actively Recruiting

Loading map...

Research Team

T

Thareerat Ananchaisarp

CONTACT

W

Wisarut Srisintorn

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here